Systemic treatments and outcomes in CIC-rearranged Sarcoma: A national multi-centre clinicopathological series and literature review

Elizabeth A. Connolly1,2,3 | Vivek A. Bhadri1,2,3,4 | Johnathon Wake4 | Katrina M. Ingle5 | Jeremy Lewin5,6,7 | Susie Bae5,7 | Daniel D. Wong8 | Anne P. Long9 | David Pryor10 | Stephen R. Thompson11,12 | Madeleine C. Strach1,2,3 | Peter S. Grimison1,2,3 | Annabelle Mahar13 | Fiona Bonar14 | Fiona Maclean14 | Angela Hong1,2,3

1Chris O’Brien Lifehouse, Sydney, New South Wales, Australia | 2Royal Prince Alfred Hospital, Sydney, New South Wales, Australia | 3Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia | 4Crown Princess Mary Cancer Centre, Westmead, Sydney, New South Wales, Australia | 5Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia | 6ONTrac at Peter Mac Victorian Adolescent & Young Adult Cancer Service | 7Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia | 8Anatomical Pathology, PathWest, QEII Medical Centre, Perth, Western Australia, Australia | 9Sir Charles Gardiner Hospital, Perth, Western Australia, Australia | 10Princess Alexandra Hospital, Brisbane, Australia | 11Princess of Wales Hospital, Sydney, New South Wales, Australia | 12Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia | 13NSW Health Pathology, Sydney, New South Wales, Australia | 14Anatomical Pathology, Douglass Hanly Moir Pathology, Sonic Healthcare, Macquarie Park, New South Wales, Australia

Abstract
CIC-rearranged sarcoma is a recently established, ultra-rare, molecularly defined sarcoma subtype. We aimed to further characterise clinical features of CIC-rearranged sarcomas and explore clinical management including systemic treatments and outcomes.

Methods: A multi-centre retrospective cohort study of patients diagnosed between 2014–2019.

Results: Eighteen patients were identified. The median age was 27 years (range 13–56), 10 patients were male (56%), 11 patients (61%) had localised disease and 7 patients had advanced (metastatic or unresectable) disease at diagnosis. Of 11 patients with localised disease at diagnosis, median overall survival (OS)
CONOLLY ET AL.

1 | INTRODUCTION

CIC-rearranged sarcoma is a recently established ultra-rare clinically and molecularly distinct subtype of high grade undifferentiated sarcoma, which is defined by CIC-related gene fusions. Due to its rarity there is a lack of consensus on how to classify and risk stratify this molecular subtype. CIC-rearranged sarcomas are small round blue cell tumours. Prior to recognition of the entity these were most likely called ‘atypical’ Ewing sarcoma or undifferentiated round cell sarcoma, not otherwise specified. They often present in younger adults (median age 25–35 years). Tumours predominantly arise in soft tissue though can arise in viscera (10%) including brain, and bone (<5%). A CIC-DUX4 fusion is present in 95% of cases, though other CIC-partners exist including FOX04, LEUTX, NUTM1 and NUTM2a.

Understanding of its natural history, clinical behaviour and treatment outcomes is limited with less than 200 cases reported in the literature and less than 100 cases include clinical follow-up or treatment information. CIC-rearranged sarcomas appear to follow an aggressive course and are linked to poorer treatment responses and survival outcomes compared to Ewing sarcoma. In the largest published series of 115 cases, of which clinical follow up information was available for 57 cases, the 2- and 5-year overall survival (OS) rates were 53% and 43%. Comprehensive information on clinical management, in particular systemic treatment use and their outcomes, is scarce.

The aim of this study was to characterise clinical features of CIC-rearranged sarcomas and evaluate clinical management, including systemic treatments and outcomes, through assessment of a series of patients from multiple institutions within Australia.

2 | MATERIALS AND METHODS

A national multi-centre retrospective cohort study was undertaken of patients with a diagnosis of CIC-rearranged sarcoma. Patients were included where a diagnosis of CIC-rearranged sarcoma had been performed by pathologists with sarcoma expertise and included fluorescence in situ hybridisation (FISH) confirmation of CIC-rearrangement. Data collection and usage for this study was approved by the Sydney Local Health Human Research Ethics Committee (X17-0340).

Patient demographics, clinical data, treatment response and outcomes were collected by retrospective record review. Systemic chemotherapy response was assessed by individual sites from the record or radiological review. Time to disease progression was defined as time from first dose of chemotherapy to time of radiological or clinical progression. Overall survival was measured from the time of diagnosis to the date of death and censored at last follow up. Progression-free survival (PFS) was defined as the time from diagnosis until the date of first progression, death, or censored.
at last follow up. A median ‘duration of systemic treatment response’ was calculated for those with advanced disease who received systemic treatment as a single modality (without concurrent surgical resection or radiotherapy). This was calculated given a number of patients with advanced disease receive multi-modality treatment in the first line, which may prolong PFS and limit evaluation of systemic therapy efficacy, and to capture the efficacy of multiple treatments used including those in the second or third line. This was defined as the time from commencing treatment until the date of radiological or clinical progression or censored at the date of last follow up. Median follow-up was calculated using a reverse Kaplan–Meier method. Survival analysis was completed by the Kaplan–Meier method with comparison of patient groups by log rank method. A p-value of less than 0.05 was considered as statistically significant. Statistical analysis was calculated using IBM SPSS statistics, version 27.

3 | RESULTS

3.1 | Patient clinicopathological characteristics

A summary of baseline characteristics is displayed in Table 1. In total, 18 patients, who were diagnosed between 2014 and 2019, were identified across 6 Australian institutions. The median age at diagnosis was 27 years (range 13–56) and 10 (56%) patients were male. Patients were aged between 20 and 40 years in 14 cases (78%). At diagnosis, 11 patients (61%) had localised disease and 7 patients had advanced (metastatic or unresectable) disease. Primary sites included soft tissue in 14 (78%) patients, visceral in 3 (17%; pleural, frontal lobe of brain without involvement of dura or skull) and bone in 1 (6%; ilium) with a median primary tumour size of 63 mm (range 27–150). Metastatic disease sites, at diagnosis and throughout disease, included lung, liver, lymph nodes, brain and bone.

All tumours represented high grade round cell undifferentiated sarcoma with sheets of cells with variable lobulation in a fibrous stroma with some nuclear pleomorphism and vesicular nuclei with prominent nucleoli. Mitotic activity was brisk, necrosis was common and in areas a myxoid stroma was noted. CD99 expression by immunohistochemistry (IHC) was noted in all cases with a patchy, variably diffuse and focally membranous appearance. WT-1 nuclear expression was noted in 79% of available cases; CD99 and WT-1 results were not available for five and four cases respectively. ETV4 IHC was positive in three out of three cases tested. EWSR1-rearrangement was tested for by FISH in 16 patients and was negative in all.

CIC-rearrangement was confirmed by FISH in all cases. DUX4 was identified as the CIC-rearrangement partner in three patients. CIC-FOX04 (case 16) and CIC-CREBBP (case 8) were identified in two patients through genomic sequencing. The rearrangement partner was not identified or available for 13 patients. Molecular profiling by next generation sequencing had been completed in six patients. No actionable variants were identified. A number of variants of uncertain significance were identified including ETV4 splice variants in two patients and an FGF4 variant in one patient. Tumour mutational burden (TMB) was reported as low in five patients, noting these were generated across different platforms without defined intervals of significance.

3.2 | Outcomes

Median follow-up was 36.8 months (range 4.6–64.2). As illustrated in Figure 1, median OS from diagnosis was 16.3 months (95% CI 9.4–23.3) with 1-, 2- and 5-year OS of 72%, 44% and 24% respectively. As illustrated in Figure 2, median PFS from diagnosis for all patients was 10.2 months (95% CI 7.6–12.8) with a 1-year PFS of 44%.

At the last follow up, of the 11 patients with localised disease, 5 (45%) patients are alive without evidence of disease and 6 (55%) developed metastatic disease with a median time to metastases of 10.5 months. Three patients (27%) developed local recurrence with a median time to local recurrence of 5.7 months. The median time to local or distant progression overall was 10.5 months (range 3.0–36.5) and all of these six patients are now deceased. The median PFS from diagnosis was 36.0 months (95% CI 0.2–71.8), median OS was 40.6 months (15.7–65.6) and the 1-, 2- and 5-year OS were 82%, 64% and 34% respectively.

Of seven patients with advanced disease at diagnosis, six are deceased and one patient remains in a complete response 27.3 months following the start of chemotherapy and 20.8 months without active therapy. In patients with advanced disease, with most receiving multi-modality therapy upfront, median PFS from diagnosis was 5.8 months (95% CI 4.5–7.2). Median OS was 12.6 months (95% CI 5.1–20.1) and 1-year OS was 57%.

3.3 | Localised disease management

Of 11 patients with localised disease at diagnosis, nine (82%) underwent surgery (all had R0 resections), eight (73%) patients received radiotherapy to the primary site and eight (73%) patients received chemotherapy.
Surgery was the initial modality of treatment in six of nine cases. Surgery was not undertaken in two cases where primary tumours were deemed unresectable after inadequate response to induction chemotherapy. Of two patients who had surgery alone, neither have developed local or distant recurrence, 37.3 and 26.2 months from surgical resection respectively.

Radiotherapy was undertaken post operatively in six patients (mean 58Gy in 30 fractions) of whom two developed local (and distant) recurrence. Definitive dose radiotherapy was utilised after chemotherapy in two cases (45Gy in 25 fractions and 50Gy in 25 fractions respectively) which were deemed unresectable. Both patients developed metastatic disease with one patient developing local recurrence also.

Chemotherapy was the initial modality of therapy in five patients and adjuvant chemotherapy was delivered after surgical resection in three patients. Where evaluable, best radiological response to neoadjuvant chemotherapy was partial in all five patients. Treatment response in the resection specimen after neoadjuvant chemotherapy was partial in all five patients. Treatment response in the resection specimen after neoadjuvant chemotherapy was partial in all five patients. Where evaluable, best radiological response to neoadjuvant chemotherapy was partial in all five patients.

### Table 1: Clinical, treatment and outcome details of 19 CIC-rearranged sarcoma diagnosed in Australia between 2014 and 2019

| Case | Age/sex | Primary | Size (mm) | Surgery, margin | Primary Site Radiotherapy (dose, fraction) |
|------|---------|---------|-----------|-----------------|-------------------------------------------|
| 1    | 38 M    | Supraclavicular mass | 56        | Y, 1 mm         | 60 Gy, 30#                                |
| 2    | 23 F    | Psoas   | 113       | N               | 50 Gy, 25#                                |
| 3    | 34 M    | Gluteus | 27        | Y, R0           | —                                          |
| 4    | 39 M    | Upper back | 100      | Y, R0           | 50 Gy, 25#                                |
| 5    | 43 F    | Chest wall | 51       | Y, R0           | 58 Gy/ 29# (with ifosfamide)               |
| 6    | 30 F    | Neck    | 60        | Y, 0.4 mm       | 66 Gy, 33#                                |
| 7    | 24 F    | Thigh   | U         | Y, R0           | —                                          |
| 8    | 31 F    | Retroperitoneum | 150     | N               | 45 Gy, 25#                                |
| 9    | 27 M    | Brain   | 65        | Y, U            | Brain 36Gy/20#, CSI 23.4Gy/ 13#            |
|      | 10      | Thigh   | 60        | Y, R0           | 55.8 Gy/ 31#                              |
|      | 11      | Thigh   | 85        | Y, R0           | —                                          |
| 12   | 22 M    | Thigh   | 115       | Y               | 50 Gy in 20# to pelvis                     |
| 13   | 56 F    | Iliac wing | 122     | Y               | 36 Gy in 12# to pelvis                     |
|      | 14      | 39 M    | Para-testicular | 50   | Y               | —                                          |
| 15   | 26 M    | Lung/ pleura | Diffuse | N              | 20 Gy in 5# to hemithorax                  |
| 16   | 27 M    | Thigh   | 59        | N               | 55 Gy in 25#                              |
| 17   | 14 F    | Lung    | 120       | Y               | 15 Gy in 10# VMAT to whole lung, 36 Gy in 18# to tumour bed |
| 18   | 21 F    | Thigh   | 60        | Y               | 20 Gy in 5# to lung                        |

Abbreviations: Adj, adjuvant; AWD, alive with disease; DOD, died of disease; F, female; Gy, grey; M, male; M, month; N, no; NACT, neo adjuvant; NED, no evidence of disease; P, palliative; R0, microscopic complete resection; R, recurrence; Rx, treatment; U, unknown; Y, yes.

Treatment regimens as detailed above.

*Censored.
who underwent resection and received chemotherapy, 3 patients (50%) developed distant recurrence between 6 and 36 months.

### Advanced disease management

Of seven patients with advanced disease at diagnosis; five underwent resection of the primary lesion (four upfront, one after pre-operative chemotherapy), six received systemic therapies (three upfront, three commenced post resection), and six received palliative dose radiotherapy (one after surgery, five after chemotherapy) to the primary site (median 43Gy in 16 fractions, treatment displayed in Table 1). Radiotherapy was used for palliative treatment of metastases including a case of spinal cord compression.

#### Systemic treatments

Systemic treatments and outcomes are summarised in Table 2. All patients with localised disease, who received chemotherapy, were treated with multi-agent regimens which were predominantly Ewing sarcoma based protocols. In advanced disease, durable responses to multiple systemic therapies were limited. The median duration of systemic treatment response, in advanced disease when 14 regimens were analysed, was 2.1 months (range 0.7–27.3). The best response to treatment in advanced disease was partial in all except one patient with oligometastatic disease who had a sustained complete response to seven cycles of vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide (VDC/IE) chemotherapy. Complete response is ongoing 27.3 months from

### Table 1

| Systemic Rx for Localised disease | Systemic Rx for Advanced disease | Sites of all metastases during disease | Disease Status | Follow up time or survival time from date of diagnosis (months) |
|----------------------------------|----------------------------------|---------------------------------------|---------------|-------------------------------------------------------------|
| —                               | AC, GD, IT                       | Lung, T4/5 soft tissue                | Local & distant R at 10 m, DOD | 29.3 |
| VDC/IE then VCDE<sup>a</sup>     | Nil (rapid progression)          | Lung, liver                           | Local & distant R at 8 m, DOD | 8.4 |
| Nil (declined Rx)                | —                                | —                                     | Alive, NED    | 37.3<sup>a</sup> |
| NA + Adj: VDC/IE                 | Nil (rapid progression)          | Lung, pleura, nodal                   | Distant R at 13 m, DOD | 16.0 |
| Adj: Epirubicin Ifosfamide       | —                                | —                                     | Alive, NED    | 27.2<sup>a</sup> |
| Adj: VDC/IE                      | —                                | —                                     | Alive, NED    | 54.3<sup>a</sup> |
| NA: VDC/IE                       | —                                | —                                     | Alive, NED    | 65.1<sup>a</sup> |
| VIDE x6, VAI x2                  | IT, etoposide                    | Lung                                  | Distant R at 11 m, DOD | 19.4 |
| Adj: Cisplatin, vincristine, lomustine cyclophosphamide | Nil (rapid progression) | Lung | Local & distant R at 6 m, DOD | 7.7 |
| NA + Adj: AI                     | Nil                              | Lung, brain, bone                     | Distant R at 36 m, DOD | 41.2 |
| —                                | VID, VAC/IE                      | Lung                                  | DOD           | 16.6 |
| —                                | Doxorubicin, VDC/IE, pembrolizumab | Lung, brain                           | DOD           | 7.6 |
| —                                | VDC/IE                           | Lung, bone                            | ANED          | 28.1<sup>y</sup> |
| —                                | VAC/IE                           | Lung, pleura, nodal                   | DOD           | 9.8 |
| —                                | VDC/IE, TC, IT                   | Lung                                  | AWD           | 14.0 |
| —                                | Ifosfamide, pazopanib            | Lung, soft tissue, brain              | DOD           | 12.7 |
| —                                | Nil (declined treatment)         | Lung                                  | DOD           | 4.7 |

Abbreviations: Adj, adjuvant; AWD, alive with disease; DOD, died of disease; F, female; Gy, grey; M, male; M, month; N, no; NACT, neo adjuvant; NED, no evidence of disease; P, palliative; R0, microscopic complete resection; R, recurrence; Rx, treatment; U, unknown; Y, yes.

<sup>a</sup>Censored.
commencing treatment, and 20.8 months from last systemic treatment. One patient received pazopanib with disease progression occurring within 30 days. One patient, with a TMB of 4.5 mutation/mb, received a single cycle of pembrolizumab with disease progression and death occurring within 30 days.
| Case ID | Disease status | Line of treatment | Medication/protocol | Number of cycles | Best response | Treatment status | Reason treatment discontinued | Time to progression (months) |
|---------|----------------|-------------------|---------------------|------------------|---------------|-----------------|-------------------------------|----------------------------|
| 12      | A              | 1                 | VID                 | 6                | PR            | Ceased          | PD                           | 4.1                        |
| 12      | A              | 2                 | VDC/IE              | 3                | PD            | Ceased          | PD                           | 3.1                        |
| 13      | A              | 2                 | VDC/IE              | 6                | PR/SD         | Ceased          | PD                           | 3.9                        |
| 14      | A              | 1                 | VDC/IE              | 7                | CR            | Ceased          | Completed                    | 27.3* months               |
| 15      | A              | 1                 | VDC/IE              | 8                | PR            | Ceased          | PD                           | 5.6                        |
| 13      | A              | 1                 | Doxorubicin         | 1                | PD            | Ceased          | PD                           | 0.8                        |
| 1       | A              | 1                 | AC                  | 3                | PD            | Ceased          | PD                           | 2.9                        |
| 1       | A              | 2                 | GD                  | 3                | PD            | Ceased          | PD                           | 2.2                        |
| 16      | A              | 2                 | TC                  | 3                | PD            | Ceased          | PD                           | 2.1                        |
| 16      | A              | 3                 | IT                  | 1                | PD            | Ceased          | PD                           | 0.8                        |
| 1       | A              | 3                 | IT                  | 2                | PD            | Ceased          | PD                           | 1.5                        |
| 8       | A              | 2                 | IT                  | 1                | NE            | Ceased          | Toxicity                     | NA                         |
| 8       | A              | 3                 | Etoposide           | 3                | PD            | Ceased          | PD                           | 2.1                        |
| 13      | A              | 3                 | Pembrolizumab       | 1                | PD            | Ceased          | PD                           | 0.7                        |
| 17      | A              | 2                 | Pazopanib           | 1                | PD            | Ceased          | PD                           | 0.8                        |

Chemotherapy as part of multi modality therapy (with surgery +/- radiotherapy)

| Case ID | Disease status | Line of treatment | Medication/protocol                                                                 | Number of cycles | Best response       | Treatment status | Reason treatment discontinued | Time to progression (months) |
|---------|----------------|-------------------|-------------------------------------------------------------------------------------|------------------|---------------------|-----------------|-------------------------------|----------------------------|
| 10      | L              | 1                 | AI                                                                                  | 5                | Metastatic relapse  | Ceased          | Completed                     | 35.8                       |
| 17      | A              | 1                 | AI                                                                                  | 6                | PR                  | Ceased          | Completed                     | 8.6                        |
| 2       | L              | 1                 | VDC/IE then VCDE from cycle 4                                                      | 6                | Metastatic relapse  | Ceased          | Completed                     | 6.5                        |
| 4       | L              | 1                 | VDC/IE                                                                             | 3                | Metastatic relapse  | Ceased          | Completed                     | 10.3                       |
| 8       | L              | 1                 | VIDEx6, VAtx2                                                                     | 8                | Metastatic relapse  | Ceased          | Completed                     | 10.2                       |
| 16      | A              | 1                 | VDC/IE                                                                             | 7                | PR                  | Ceased          | Completed, PD                 | 6.0                        |
| 9       | L              | 1                 | Cisplatin, vincristine, lomustine then cyclophosphamide                            | U                | Metastatic relapse  | Ceased          | Completed                     | 5.0                        |
| 6       | L              | 1                 | VDC/IE                                                                             | 7                | Disease free        | Ceased          | Completed                     | —                          |
| 7       | L              | 1                 | VDC/IE                                                                             | 7                | Disease free        | Ceased          | Completed                     | —                          |
| 5       | L              | 1                 | Epirubicin ifosfamide, chemoradiation with ifosfamide                             | 7                | Disease free        | Ceased          | Completed                     | —                          |

Abbreviations: A, advanced; CR complete response; L, localised; PD progressive disease; PR, partial response; SD stable disease. Treatment regimens as detailed above.
DISCUSSION

CIC-rearranged sarcoma is a rare and only recently recognised distinct entity, with a paucity of published literature. Our study confirms the unique characteristics and poor prognosis of CIC-rearranged sarcoma. To the best of our knowledge, we present the first clinical series to comprehensively detail individualised systemic treatment use and to summarise available literature.

We report that although these tumours have a predilection to arise in soft tissue, they can present as primary lesions in other sites such as bone or brain. The latter two have been detailed only infrequently.5–7 This cohort confirms these tumours arise in young adults, with 78% of cases in this series arising in those aged 20–40 years. The majority of cases appear to arise in patients aged 40 years and below in available case series (59%–71% of patients).6–8 However, a wide age range from 6 to 83 years has been described.2,8

The prognosis of patients with CIC-rearranged sarcomas was poor and consistent with previous reports. In this study, median OS for the overall cohort was 16.3 months with the 2- and 5-year OS of 44% and 24% respectively. Median OS was 40.6 months in those presenting with localised disease at diagnosis and only 12.6 months in those presenting with advanced disease. Disease recurrence occurred in 55% of those presenting with localised disease at diagnosis. In the largest available series of 115 cases, of which clinical follow up was available for 57 patients, Antonescu et al. report 2 and 5-year OS rates of 59% and 49% respectively.2 Yoshida et al. reviewed 20 cases and reported a median OS of 12 months, an estimated 5-year OS of 17%, and detailed 13 of 20 (65%) patients to be deceased secondary to disease 3–19 months after diagnosis.6 Brady et al. detailed 12 cases of CIC-rearranged sarcoma of which three patients (25%) died between 4 and 19 months of initial presentation.5

The usual management for localised disease in this series was surgical resection, with peri-operative chemotherapy using Ewing sarcoma-based regimens and adjuvant radiation, after which 55% developed metastases at a median of 10.5 months, and 27% failed locally at a median of 5.7 months. Long-term disease-free survival has been achieved with both multi-modality therapy and with resection alone.

CIC-rearranged sarcomas consistently appear to be less chemo-sensitive than Ewing sarcomas. This is illustrated by the high frequency of relapse in localised disease and short durations of treatment response in the advanced setting. In this series, and available literature, partial responses to systemic therapy occur (Table 4). However, our findings demonstrated that responses are short-lived, suggesting rapid development of treatment resistance. Systemic treatment survival outcomes, and treatment response, in available literature are summarised in Tables 3 and 4.

When considering the treatment approach for localised disease, the authors would advocate consideration for initial resection, rather than neo-adjuvant therapy, given the efficacy of chemotherapy in the localised setting is unclear and delayed resection may increase metastatic risk. One patient (case 2) in this series developed local progression while receiving initial systemic therapy and progression on pre-operative chemotherapy has also been cited by Italiano et al.9 This viewpoint is further supported by Antonescu et al. who found patients treated with neo-adjuvant chemotherapy (n = 22) showed an inferior survival compared with patients managed by surgery first (n = 29) (p = 0.025). It was noted, however, that patients selected for neo-adjuvant therapy had a larger tumour size (p < 0.0001) compared with patients who were managed by surgery first which may have confounded the findings.2

When considering the utility of neo-adjuvant chemotherapy to down-stage disease and improve surgical morbidity, partial responses to therapy were observed. However, no complete responses of localised disease occurred in this series nor are detailed in the literature.

When reviewing neo-adjuvant treatment response, three patients were available for evaluation; pathological response of more than 90% necrosis (case 10) and less than 50% necrosis (case 4) were observed after neo-adjuvant chemotherapy and radiotherapy, and, 50% necrosis (case 7) after pre-operative chemotherapy alone. The utility of pathological response in CIC-rearranged sarcoma as a surrogate marker of prognosis, as has been established in Ewing sarcoma and osteosarcoma,10,11 has not been shown; case 11 who had a superior pathological response had a long disease-free interval (36 months) although ultimately developed fatal disease recurrence and case 8, who had an inferior response, achieved long term disease control without recurrence (disease free at 59 months). This is in keeping with Antonescu et al. who found no correlation between survival and the degree of response when 10 patients were analysed including 3 patients who had achieved greater than 90% therapy-related change.5

In advanced disease, durable responses to systemic therapy appear to be limited (Tables 2 and 4) with no agent or regimen demonstrating clear efficacy. One exceptional response to VDC/IE (case 14) was seen. Yoshida et al. also detail a similar exceptional response, of a duration of at least 79 months, with treatment including VDC/IE, topotecan and cyclophosphamide.6 Sequential VDC followed by second-line IE chemotherapy has been used, providing disease control for approximately 12 months.12 Italiano et al. reported a complete response of metastatic disease to doxorubicin and ifosfamide.9 The duration of response, however, was not reported. In available literature, OS in advanced
### TABLE 3  Literature summary of overall survival of 42 patients with systemic treatment use. Organised by first line treatment regimen and localised or advanced disease at diagnosis

| Localised/advanced disease at diagnosis | Regimen | Author | ID | Disease Status | Follow up time or survival time from date of diagnosis (months) | Survival rate at 6 months | Survival rate at 12 months |
|----------------------------------------|---------|--------|----|----------------|---------------------------------------------------------------|---------------------------|---------------------------|
| Localised                              |         |        |    |                |                                                               |                           |                           |
| Localised Ewings-based 1st line regimen |         |        |    |                |                                                               |                           |                           |
| VIDE, VAI                              | Brcic 2020 | 2     | NED | 30†           |                                                               | 100%                      | 45%                       |
| VIDE                                   | Brcic 2020 | 5     | DOD | 8             |                                                               |                           |                           |
| VIDE                                   | Brcic 2020 | 6     | DOD | 6             |                                                               |                           |                           |
| “Ewing protocol” (neoadjuvant)         | Mangray 2018 | 2     | DOD | 6             |                                                               |                           |                           |
| VDC (adjuvant)                         | Mangray 2018 | 3     | AWD | 8†           |                                                               |                           |                           |
| CODE, VDC-I                            | Yoshida 2016 | 10    | AWD | 6†           |                                                               |                           |                           |
| *as per Table 1*                       | Connolly 2022* | 2,4,6-8 | — | —           |                                                               |                           |                           |
| Localised                              | Anthracycline-containing soft tissue sarcoma-based 1st line regimen |        |    |                |                                                               | 100%                      | 67%                       |
| AI                                     | Brcic 2020 | 1     | DOD | 10           |                                                               |                           |                           |
| AI (adjuvant)                          | Mangray 2018 | 1     | NED | 36†          |                                                               |                           |                           |
| AI + dacarbazine                       | Yoshida 2016 | 8     | NED | 14†          |                                                               |                           |                           |
| AI                                     | Yoshida 2016 | 15    | NED | 7†          |                                                               |                           |                           |
| *as per Table 1*                       | Connolly 2022* | 5,10  | — | —           |                                                               |                           |                           |
| Advanced                                |         |        |    |                |                                                               |                           |                           |
| Ewings-based 1st line regimen          |         |        |    |                |                                                               | 100%                      | 59%                       |
| VDC × 3, VAC × 3, IE, trabectedin      | Kimbara 2021 | 1     | DOD | 13           |                                                               |                           |                           |
| VIDE, IT + Bevacizumab                 | Brcic 2020 | 3     | DOD | 15           |                                                               |                           |                           |
| VAIA, pazopanib                        | Brcic 2020 | 4     | DOD | 14           |                                                               |                           |                           |
| AI/VAC, gemcitabine + paclitaxel, ifosfamide (high dose) | Sedighim 2020 | 1 | DOD | 15           |                                                               |                           |                           |
| VDC/IE × 7, VAI × 2, SCT, pazopanib, IT | Nakai 2019 | 1     | DOD | 16           |                                                               |                           |                           |
| VDC/IE                                 | Yoshida 2016 | 6     | DOD | 8            |                                                               |                           |                           |
| VAC, VDC/IE, TC, paclitaxel            | Yoshida 2016 | 9     | DOD | 6            |                                                               |                           |                           |
| VDC/IE, cisplatin/irinotecan, AI       | Yoshida 2016 | 12    | DOD | 10           |                                                               |                           |                           |

(Continues)
### Table 3 (Continued)

| Localised/advanced disease at diagnosis | Regimen | Author     | ID | Disease Status | Follow up time or survival time from date of diagnosis (months) | Survival rate at 6 months | Survival rate at 12 months |
|----------------------------------------|---------|------------|----|---------------|---------------------------------------------------------------|--------------------------|---------------------------|
| VAC/VDC/IE, irinotecan, TC             | Yoshida | 2016       | 14 | DOD           | 11                                                            |                          |                           |
| VDC/IE, TC                            | Yoshida | 2016       | 16 | ANED          | 74†                                                           |                          |                           |
| VDC, I                                | Yoshida | 2016       | 17 | DOD           | 12                                                            |                          |                           |
| VDC/IE, VACA, ICE                     | Yoshida | 2016       | 18 | DOD           | 9                                                             |                          |                           |
| VDC/IE, VIDE                          | Yoshida | 2016       | 19 | AWD           | 7†                                                            |                          |                           |
| as per Table 1                         | Connolly| 2022*      | 13,15–17 | —           | —                                                             |                          |                           |

#### Advanced

**Anthracycline-containing soft tissue sarcoma-based 1st line regimen**

| Stage | Regimen                                  | Author     | ID | Disease Status | Follow up time or survival time from date of diagnosis (months) | Survival rate at 6 months | Survival rate at 12 months |
|-------|------------------------------------------|------------|----|---------------|---------------------------------------------------------------|--------------------------|---------------------------|
| AI    | AI                                       | Yoshida    | 1  | DOD           | 8                                                            |                          |                           |
| AI, VAIA, gemcitabine                  | Yoshida    | 2016       | 3  | DOD           | 19                                                            |                          |                           |
| AI, Pazopanib                          | Yoshida    | 2016       | 4  | DOD           | 13                                                            |                          |                           |
| AI, Gemcitabine, Docetaxel             | Yoshida    | 2016       | 5  | DOD           | 14                                                            |                          |                           |
| Doxorubicin                            | Yoshida    | 2016       | 7  | DOD           | 4                                                             |                          |                           |
| Doxorubicin, dacarbazine               | Yoshida    | 2016       | 11 | DOD           | 3                                                             |                          |                           |
| AI, pazopanib                          | Yoshida    | 2016       | 20 | DOD           | 18                                                            |                          |                           |
| as per Table 1                         | Connolly   | 2022*      | 14 | —            | —                                                             |                          |                           |

†remains alive

Abbreviations: ANED, alive no evidence of disease; AWD, alive with disease; DOD, died of disease.

Treatment regimens as detailed above.

* Reflects patients from this series.
disease appears to be similar whether multi-agent Ewing based regimens (1-year OS 59%), or soft tissue anthracycline doxorubicin based regimens (1-year OS 50%), are used in the first line (Table 3). The small numbers included when considering these survival statistics, in particular those who have received anthracycline containing soft tissue sarcoma-based treatment, must however be considered.

Our series adds to limited reports of molecularly targeted therapies and immunotherapeutics in CIC-rearranged sarcoma.7,13–15 Unfortunately, treatment efficacy was not demonstrated in our patients treated with pazopanib and pembrolizumab, with rapid disease progression occurring in both. Of patients who underwent genomic sequencing, no actionable mutations nor therapeutic options were identified. There is a paucity of individualised systemic therapy outcome (progression free survival) evidence in current literature for all treatments and the efficacy of non-anthracycline-containing soft tissue sarcoma regimens, molecularly targeted therapies and immunotherapy remains to be determined.

Our study has several limitations including its retrospective nature, small sample size, and potential for selection bias. A centralised pathological review has not been undertaken, however, there is a high level of certainty of diagnosis as all diagnoses were made at specialised sarcoma centres and CIC-rearrangement has been confirmed with FISH in all cases.

In future, international collaboration will be required to determine therapeutic approaches and to develop consensus guidelines. Further research is needed to better understand the unique disease biology of this entity, to develop novel therapeutics, and to identify biomarkers of disease response, especially in exceptional responders. Access to early phase clinical trials, and translational research, will be key in identifying efficacious novel agents from which CIC-specific clinical trials could follow. Although challenging, subtype-specific trials of ultra-rare sarcomas are possible through international collaboration as evidenced by the ‘CASPS’ trial of cediranib for alveolar soft part sarcoma18 and the phase 2 basket trial of tazemetostat for epithelioid sarcoma.17

In conclusion, in this series CIC-rearranged sarcoma affected young adults with a high incidence of presenting with, or developing, metastatic disease. Prognosis overall was poor with a median OS of 16.3 months. Usual management for localised disease was surgical resection, chemotherapy with Ewing-based regimens, and adjuvant radiation, after which 55% developed metastases at a median time to progression of 10.5 months. In advanced disease, durable systemic therapy responses occurred infrequently with a median duration of systemic treatment response of 2.1 months. Radiotherapy to the primary site was used frequently in localised and advanced disease. Further research through international collaboration is needed to establish optimum treatment approaches for localised and advanced disease.

ACKNOWLEDGMENTS
The authors thank the patients reported in this study and the Australia and New Zealand Sarcoma Association (ANZSA) who supported this study. The article is dedicated to the memory of Dr Annabelle Mahar.
CONFLICTS OF INTEREST
The authors declare that there is no conflict of interest regarding the publication of this article.

AUTHOR CONTRIBUTIONS
Conception and design: EC, AH; Financial support: none; Administrative support: EC, AH;
Data analysis and interpretation: EC, VB, JW, PG, MS, FB, AH;
Provision of study materials or patients, collection and assembly of data, manuscript writing, and final approval of manuscript: all authors.

ETHICS STATEMENT
Data collection and usage for this study was approved by the Sydney Local Health Human Research Ethics Committee (X17-0340).

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Elizabeth A. Connolly https://orcid.org/0000-0002-5579-3728

TWITTER
Elizabeth A. Connolly @DrLizConnolly

REFERENCES
1. Stacchiotti S, Frezza AM, Blay JY, et al. Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021;127:2934-2942.
2. Antonescu CR, Owosho AA, Zhang L, et al. Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome: a clinicopathologic and molecular study of 115 cases. Am J Surg Pathol. 2017;41(7):941-949.
3. Board WCoTe. WHO Classification of Tumours of Soft Tissue and Bone. Vol. 3. 5th ed. IARC; 2020.
4. Kinnaman MD, Zhu C, Weiser DA, et al. Survey of paediatric oncologists and pathologists regarding their views and experiences with variants in translocations in ewing and ewing-like sarcoma: a report of the children’s oncology group. Sarcoma. 2020;2020:3498549-9.
5. Brady EJ, Hameed M, Tap WD, Hwang S. Imaging features and clinical course of undifferentiated round cell sarcomas with CIC-DUX4 and BCOR-CCNB3 translocations. Skelet Radiol. 2021;50(3):521-529.
6. Yoshida A, Goto K, Kodaira M, et al. CIC-rearranged sarcomas: a study of 20 cases and comparisons with ewing sarcomas. Am J Surg Pathol. 2016;40(3):313-323.
7. Bric I, Brodowicz T, Cerroni L, et al. Undifferentiated round cell sarcomas with CIC-DUX4 gene fusion: expanding the clinical spectrum. Pathology. 2020;52(2):236-242.
8. Le Guelllec S, Velasco V, Perot G, Watson S, Tirode F, Coindre JM. ETV4 is a useful marker for the diagnosis of CIC-rearranged undifferentiated round-cell sarcomas: a study of 127 cases including mimicking lesions. Mod Pathol. 2016;29(12):1523-1531.
9. Italiano A, Sung YS, Zhang L, et al. High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes Chromosomes Cancer. 2012;51(3):207-218.
10. Bramer JA, van Linge JH, Grimer RJ, Scholten RJ. Prognostic factors in localized extremism osteosarcoma: a systematic review. Eur J Surg Oncol. 2009;35(10):1030-1036.
11. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol. 2000;18(17):3108-3114.
12. Kimbara S, Imamura Y, Kiyota N, et al. Secondary CIC-rearranged sarcoma responsive to chemotherapy regimens for Ewing sarcoma: a case report. Mol Clin Oncol. 2021;14(4):68.
13. Yoshida A, Arai Y, Kobayashi E, et al. CIC break-apart fluorescence in-situ hybridization misses a subset of CIC-DUX4 sarcomas: a clinicopathological and molecular study. Histopathology. 2017;71(3):461-469.
14. Nakai S, Yamada S, Outani H, et al. Establishment of a novel human CIC-DUX4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs. Sci Rep. 2019;9(1):15812.
15. Ricker CA, Berlow NE, Crawford KA, et al. Undifferentiated small round cell sarcoma in a young male: a case report. Cold Spring Harb Mol Case Stud. 2020;6(1):a004812.
16. Judson I, Morden JP, Kilburn L, et al. Cediranib in patients with alveolar soft-part sarcoma (CASP5): a double-blind, placebo-controlled, randomised, phase 2 trial. Lancet Oncol. 2019;20(7):1023-1034.
17. Gounder M, Schöffski P, Jones RL, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020;21(11):1423-1432.
18. Choi EY, Thomas DG, McHugh JB, et al. Undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC-DUX4 fusion: a novel highly aggressive soft tissue tumor with distinctive histopathology. Am J Surg Pathol. 2013;37(9):1379-86.
19. Sedighim S, Burke J, Schneider D, et al. CIC-rearranged round cell (Ewing-like) sarcoma of the uterus: Review of the literature. Gynecol Oncol Rep. 2020;33, 100592.
20. Nakai S, Yamada S, Outani H, et al. Establishment of a novel human CIC-DUX4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs. Sci Rep. 2019;9(1):15812.

How to cite this article: Connolly EA, Bhadri VA, Wake J. Systemic treatments and outcomes in CIC-rearranged Sarcoma: A national multi-centre clinicopathological series and literature review. Cancer Med. 2022;11:1805–1816. doi: 10.1002/cam4.4580